Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alcon Inc (NY: ALC ) 96.09 +0.76 (+0.80%) Official Closing Price Updated: 7:00 PM EDT, Aug 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alcon Inc < Previous 1 2 3 4 5 6 7 Next > Alcon Analysts Increase Their Forecasts After Q2 Results August 22, 2024 Via Benzinga ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q2 2024 August 20, 2024 ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace Alcon Reports Second-Quarter 2024 Results with Strong Growth in Implantables and Contact Lenses August 20, 2024 From Alcon Inc. Investors Via Business Wire S&P 500, Nasdaq Extend Gains For 8th Consecutive Session: Investor Sentiment Improves, But Greed Index Remains In 'Fear' Zone August 20, 2024 Via Benzinga Topics Stocks Exposures US Equities Lowe's, Palo Alto Networks And 3 Stocks To Watch Heading Into Tuesday August 20, 2024 Via Benzinga Alcon Analysts Increase Their Forecasts Following Q1 Results May 15, 2024 Via Benzinga Alcon Inc. (NYSE: ALC) Records 52-Week High Tuesday Morning March 12, 2024 Via Investor Brand Network Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED August 17, 2024 Japan’s Eisai Pharma formed a collaboration with SEED, a Pennsylvania biotech, to develop molecular glues for targeted protein degradation of disease-causing proteins. SEED is eligible to receive up to... Via Talk Markets US Stocks Trim Gains As Iran Mulls Attack On Israel; Gold, Oil Rally: What's Driving Markets Monday? August 12, 2024 Wall Street turns negative due to geopolitical risks. Gold rises 1.5% and stocks edge higher. Scotiabank acquires minority stake in KeyCorp. Via Benzinga Nasdaq, S&P 500 Futures Climb After Volatile Week As Traders Eye Inflation Data and Retail Earnings: Strategist Says Not CPI But This Data Can Give People Lot Of Conviction August 12, 2024 The resilience of the market was in full display on Monday after last week’s “historical comeback” by the market. The major index futures traded higher, albeit by a modest magnitude. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock? July 16, 2024 Johnson & Johnson has beaten earnings per share in more than 10 straight quarters. Will the trend continue in Q2? Via Benzinga Alcon’s Latest Equipment Breakthrough Technologies, Unity VCS and Unity CS, Receive U.S. FDA 510(k) Clearance June 24, 2024 From Alcon Inc. Investors Via Business Wire ALC Stock Earnings: Alcon Beats EPS, Misses Revenue for Q1 2024 May 20, 2024 ALC stock results show that Alcon beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Do You Have Your Eye On Vision Care Stocks? May 20, 2024 For investors seeking stable and growing opportunities, eye care stocks are an attractive option. Via Talk Markets MicroStrategy Was The Best Among These 10 Large-Cap Stocks Scoring Big Last Week (May 12-May 19, 2024): Are They In Your Portfolio? May 19, 2024 Top performing large-cap stocks in the last week: MSTR, MNDY, ONON, SE, PODD, DELL, VOD, ALC, SMCI, CRBG. Analysts raise price targets & more positive news. Via Benzinga Contact Lens Maker Alcon's Has New Growth Avenues, Analyst Upgrades Stock May 15, 2024 Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment options, enhanced PanOptix IOL, and market advancements in China. Via Benzinga Why Alibaba Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session May 14, 2024 Via Benzinga Sony Group Posts Upbeat Earnings, Joins GameStop, Paysafe And Other Big Stocks Moving Higher On Tuesday May 14, 2024 Via Benzinga Why Alcon Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket May 14, 2024 Via Benzinga 2 Intriguing Medical Stocks To Buy For Steady Growth As Earnings Approach May 14, 2024 Among the medical sector, Alcon and Prestige Consumer Healthcare are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14. Via Talk Markets Alcon Reports Strong First-Quarter 2024 Results Driven by Robust Sales in Contact Lenses and Ocular Health May 13, 2024 From Alcon Inc. Investors Via Business Wire Alcon Announces Results of 2024 Annual General Meeting May 08, 2024 From Alcon Inc. Investors Via Business Wire Star Surgical Shines as U.S. Outlook Improves for 2024 April 16, 2024 STAAR Surgical is increasing its outlook and guidance as demand for its signature IOL procedure increases with an aging population Via MarketBeat Alcon Publishes Agenda for 2024 Annual General Meeting April 07, 2024 From Alcon Inc. Investors Via Business Wire Vivity, the World’s Leading EDOF IOL, Reaches One Million Milestone March 06, 2024 From Alcon Inc. Corporate Via Business Wire Alcon's Broad Portfolio Delivers Robust Sales and Earnings Growth in FY 2023 February 27, 2024 From Alcon Inc. Investors Via Business Wire Earnings Preview: What To Expect To When Eye Health Company Bausch + Lomb Reports Q4 Performance Later This Month February 09, 2024 "Bausch + Lomb's Q4 & FY 2023 results on Feb 21, 2024. Expecting $1.107 billion in sales, $0.17 EPS. RBC Capital predicts $1.159 billion revenue. Insights on Miebo launch and enhanced EBITDA margins... Via Benzinga Buy This Ophthalmology Stock But Sell This One, Says Bernstein Analyst: 'Innovation Is Key' January 23, 2024 Innovation and digitalization have been in focus among ophthalmology majors. Via Benzinga Good News For Dry Eye Disease Patients: Eye Care Focused Alcon's Treatment Shows Encouraging Benefit In Late-Stage Trials January 10, 2024 Alcon (NYSE: ALC) released topline results from the two Phase 3 trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, a candidate treatment for the signs and symptoms of Via Benzinga Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye January 09, 2024 From Alcon Inc. Investors Via Business Wire < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.